Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-Current Debt: 2018-2025

Historic Non-Current Debt for Arcturus Therapeutics Holdings (ARCT) over the last 4 years, with Mar 2025 value amounting to $15.0 million.

  • Arcturus Therapeutics Holdings' Non-Current Debt was N/A to $15.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.0 million, marking a year-over-year change of. This contributed to the annual value of $40.6 million for FY2021, which is 193.49% up from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Non-Current Debt stood at $15.0 million for Q1 2025, which was down 25.00% from $20.0 million recorded in Q3 2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Non-Current Debt registered a high of $58.1 million during Q1 2021, and its lowest value of $15.0 million during Q1 2025.
  • Moreover, its 2-year median value for Non-Current Debt was $17.5 million (2023), whereas its average is $17.5 million.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Non-Current Debt skyrocketed by 286.92% in 2021 and then slumped by 37.57% in 2023.
  • Over the past 4 years, Arcturus Therapeutics Holdings' Non-Current Debt (Quarterly) stood at $40.6 million in 2021, then dropped by 24.34% to $32.0 million in 2022, then plummeted by 37.57% to $20.0 million in 2023, then reached $15.0 million in 2025.
  • Its Non-Current Debt stands at $15.0 million for Q1 2025, versus $20.0 million for Q3 2023 and $32.0 million for Q3 2022.